Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.
Conditions
Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis, Protozoa
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leishmaniasis, Cutaneous
Interventions
WR 279,396
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

NCT01751048
Conditions
Leishmaniasis
Interventions
GLA-SE, LEISH-F3, MPL-SE, SE
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous
Interventions
sodium stibogluconate (Pentostam)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
San Francisco, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development of a Skin Test for the Na-ASP-2 Hookworm Antigen

NCT00603889
Conditions
Hookworm Infection, Allergy
Interventions
Na-ASP-2 Skin Test Reagent
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Pediculosis
Interventions
Spinosad, Permethrin 1%
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
6 Months and older
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 3 more
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Completed Phase 2 Interventional Results available

Sodium Stibogluconate Treatment of Leishmaniasis

NCT00662012
Conditions
Leishmaniasis
Interventions
Sodium Stibogluconate (SSG)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Cutaneous Leishmaniasis
Interventions
Paromomycin +Gentamicin topical cream
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Pediculosis
Interventions
lousebuster
Device
Lead sponsor
Larada Sciences, Inc.
Industry
Eligibility
6 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Scabies
Interventions
Spinosad Topical
Drug
Lead sponsor
Cipher Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 4 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Miami, Florida • Lafayette, Louisiana • Houston, Texas
Conditions
Cutaneous Leishmaniasis
Interventions
Leishmania tropica Skin Test Antigen (LtSTA), Leishmania tropica Skin Test Antigen Placebo (Placebo)
Biological
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Conditions
Scabies
Interventions
Permethrin Cream, 5%, Elimite
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Richland, Washington
Conditions
Lice; Head Lice
Interventions
Medical Device (X92001483)
Device
Lead sponsor
Oystershell NV
Industry
Eligibility
1 Year and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Maitland, Florida
Completed No phase listed Observational Accepts healthy volunteers

PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei

NCT02254564
Conditions
Scabies
Interventions
Not listed
Lead sponsor
Seton Healthcare Family
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
5
States / cities
Austin, Texas • Lockhart, Texas
Completed Phase 2 Interventional Results available

Miltefosine to Treat Mucocutaneous Leishmaniasis

NCT01050907
Conditions
Mucosal Leishmaniasis, Cutaneous Leishmaniasis
Interventions
Miltefosine
Drug
Lead sponsor
Knight Therapeutics (USA) Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Cutaneous Leishmaniasis
Interventions
Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Clinical Investigation of Infections Due to Leishmanial Parasites

NCT00001169
Conditions
Leishmaniasis, Leishmaniasis, Visceral
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1979 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis, Onchocerciasis
Interventions
Diethylcarbamazine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Scabies
Interventions
spinosad topical suspension, 0.9%, Placebo
Drug · Other
Lead sponsor
ParaPRO LLC
Industry
Eligibility
4 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Long Beach, California • Kissimmee, Florida + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers

NCT02071758
Conditions
Visceral Leishmaniasis
Interventions
LEISH-F3 + SLA-SE, LEISH-F3 + GLA-SE
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 49 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Lice; Head Lice
Interventions
Ivermectin Lotion, 0.5%, SKLICE (ivermectin) Lotion, 0.5%, Vehicle of the Test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Hawthorne, New York
Conditions
Leishmaniasis, Cutaneous
Interventions
Paromomycin
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
U.S. locations
2
States / cities
Bethesda, Maryland • Multiple Locations, Maryland
Conditions
Skin Diseases
Interventions
Not listed
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York